Continuous and Intermittent Glucose Monitoring in 2022

Kieu A , King J , Govender RD , Östlundh L. The benefits of utilizing continuous glucose monitoring of diabetes mellitus in primary care: a systematic review. J Diabetes Sci Technol 2022 Feb 1;19322968211070855. doi: 10.1177/19322968211070855. Online ahead of print.

Raj R , Mishra R , Jha N , Joshi V , Correa R , Kern PA . Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review. BMJ Open Diab Res Care, 2022; 10: e002573.

Steck AK , Dong F , Rasmussen CG , et al. CGM metrics predict imminent progression to type 1 diabetes: autoimmunity screening for kids (ASK) study. Diabetes Care. 2022; 45: 365–71.

Smigoc Schweiger D. Recent advances in immune-based therapies for type 1 diabetes. Horm Res Paediatr 2022 May 9. doi: 10.1159/000524866. Online ahead of print.

Sims EK , Besser REJ , Dayan C , et al. Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes, 2022; 71: 610–23.

Steck AK , Dong F , Taki I , et al. Continuous glucose monitoring predicts progression to diabetes in autoantibody positive children. J Clin Endocrinol Metab, 2019; 104: 3337–44.

Karl FM , Winkler C , Ziegler AG , Laxy M , Achenbach P . Costs of public health screening of children for presymptomatic type 1 diabetes in Bavaria, Germany. Diabetes Care, 2022; 45: 837–44.

Carr ALJ , Evans-Molina C , Oram RA . Precision medicine in type 1 diabetes. Diabetologia, 2022; 285: 40–48.

Rickels MR , Evans-Molina C , Bahnson HT , et al. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest, 2020; 130: 1850–62.

Herold KC , Bundy BN , Long SA , et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med, 2019; 381: 603–13.

Weiss A , Zapardiel-Gonzalo J , Voss F , et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia 2022; 2022 Aug 27. doi: 10.1007/s00125-022-05780-9. Online ahead of print.

Cardona-Hernandez R , Schwandt A , Alkandari H , et al. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the international pediatric registry SWEET. Diabetes Care, 2021; 44: 1176–84.

Bolinder J , Antuna R , Geelhoed-Duijvestijn P , et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet, 2016; 388(10057): 2254–63.

Beck RW , Riddlesworth T , Ruedy K , et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections the diamond randomized clinical trial. JAMA, 2017; 317: 371–78.

Heinemann L , Freckmann G , Ehrmann D , et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet, 2018; 391(10128): 1367–77.

Laffel LM , Kanapka LG , Beck RW , et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA, 2020; 323: 2388–96.

Pratley RE , Kanapka LG , Rickels MR , et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. JAMA, 2020; 323: 2397–406.

DiMeglio LA , Kanapka LG , DeSalvo DJ , et al. A randomized clinical trial assessing continuous glucose monitoring (CGM) use with standardized education with or without a family behavioral intervention compared with fingerstick blood glucose monitoring in very young children with type 1 diabetes. Diabetes Care, 2021; 44: 464–72.

Dovc K , Van Name M , Jenko Bizjan B , et al. Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): a multinational prospective observational real-world cohort study. Diabetes Obes Metab, 2022; 24: 564–69.

Champakanath A , Akturk HK , Alonso GT , Snell-Bergeon JK , Shah VN . Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study. Diabetes Care, 2022; 45: 750–53

Sanderson EE , Abraham MB , Smith GJ , Mountain JA , Jones TW , Davis EA . Continuous glucose monitoring improves glycemic outcomes in children with type 1 diabetes: real-world data from a population-based clinic. Diabetes Care, 2021; 44: e171–72.

Foster NC , Beck RW , Miller KM , et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther, 2019; 21: 66–72.

Deshmukh H , Wilmot EG , Gregory R , et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit. Diabetes Care, 2020; 43: 2153–60.

Johnson SR , Holmes-Walker DJ , Chee M , Earnest A , Jones TW . Universal subsidized continuous glucose monitoring funding for young people with type 1 diabetes: uptake and outcomes over 2 years, a population-based study. Diabetes Care, 2022; 45: 391–97.

Burckhardt M-A , Abraham MB , Mountain J , et al. Improvement in psychosocial outcomes in children with type 1 diabetes and their parents following subsidy for continuous glucose monitoring. Diabetes Technol Ther, 2019; 21: 575–80.

Charleer S , De Block C , Van Huffel L , et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care, 2020; 43: 389–97.

Rotondi MA , Wong O , Riddell M , Perkins B . Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently scanned continuous glucose monitoring technologies for adults with type 1 diabetes in Canada: a modeling study. Diabetes Care, 2022; 45: 2012–19.

Rabbone I , Savastio S , Pigniatiello C , et al. Significant and persistent improvements in time in range and positive emotions in children and adolescents with type 1 diabetes using a closed-loop control system after attending a virtual educational camp. Acta Diabetol, 2022; 59: 837–42.

Hermanns N , Ehrmann D , Shapira A , Kulzer B , Schmitt A , Laffel L. Coordination of glucose monitoring, self-care behaviour and mental health: achieving precision monitoring in diabetes. Diabetologia 2022 Apr 5. doi: 10.1007/s00125-022-05685-7. Online ahead of print.

Nimri R , Tirosh A , Muller I , et al. Comparison of Insulin dose adjustments made by artificial intelligence-based decision support systems and by physicians in people with type 1 diabetes using multiple daily injections therapy. Diabetes Technol Ther, 2022; 24: 564–72.

Weinstock RS , DuBose SN , Bergenstal RM , et al. Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. Diabetes Care, 2016; 39: 603–10.

Punthakee Z , Miller ME , Launer LJ , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care, 2012; 35: 787–93.

Battelino T , Danne T , Bergenstal RM , et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care, 2019; 42: 1593–603.

Weinstein JM , Kahkoska AR . Association of continuous glucose monitoring use and hemoglobin A1c levels across the lifespan among individuals with type 1 diabetes in the US. JAMA Netw Open, 2022; 5(7): E2223942.

Miller KM , Kanapka LG , Rickels MR , et al. Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24: 424-434.

Scott EM , Murphy HR , Kristensen KH , et al. Continuous glucose monitoring metrics and birth weight: informing management of type 1 diabetes throughout pregnancy. Diabetes Care, 2022; 45: 1724-1734.

Perea V , Picón MJ , Megia A , et al. Addition of intermittently scanned continuous glucose monitoring to standard care in a cohort of pregnant women with type 1 diabetes: effect on glycaemic control and pregnancy outcomes. Diabetologia. 2022; 65: 1302–14.

Feig DS , Donovan LE , Corcoy R , et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet, 2017; 390(10110): 2347–59.

American Diabetes Association Professional Practice Committee. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022. Diabetes Care, 2022; 45(Suppl 1): S232–43.

Visser MM , Charleer S , Fieuws S , et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet, 2021; 397(10291): 2275–83.

Deiss D , Irace C , Carlson G , Tweden KS , Kaufman FR . Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: a post-market registry study. Diabetes Technol Ther, 2020; 22: 48–52.

Irace C , Cutruzzolà A , Nuzzi A , et al. Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. Diabetes Obes Metab, 2020; 22: 1056–61.

Kropff J , Choudhary P , Neupane S , et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 2017; 40: 63–68.

Sanchez P , Ghosh-Dastidar S , Tweden KS , Kaufman FR . Real-World Data from the First U.S. Commercial users of an implantable continuous glucose sensor. Diabetes Technol Ther, 2019; 21: 677–81

Jafri RZ , Balliro CA , El-Khatib F , et al. A Three-way accuracy comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense Continuous glucose monitoring devices in a home-use study of subjects with type 1 diabetes. Diabetes Technol Ther, 2020; 22: 846–52.

Garg SK , Liljenquist D , Bode B , et al. Evaluation of accuracy and safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: the PROMISE Study. Diabetes Technol Ther, 2022; 24: 84–92.

Renard E , Riveline JP , Hanaire H , Guerci B . Reduction of clinically important low glucose excursions with a long-term implantable continuous glucose monitoring system in adults with type 1 diabetes prone to hypoglycaemia: the France Adoption Randomized Clinical Trial. Diabetes Obes Metab, 2022; 24: 859–67.

Marigliano M , Eckert AJ , Guness PK , et al. Association of the use of diabetes technology with HbA1c and BMI-SDS in an international cohort of children and adolescents with type 1 diabetes: The SWEET project experience. Pediatr Diabetes, 2021; 22: 1120–8.

Teo E , Hassan N , Tam W , Koh S . Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia, 2022; 65: 604–19.

Peek ME , Thomas CC . Broadening access to continuous glucose monitoring for patients with type 2 diabetes. JAMA, 2022; 325: 2255–57.

Karter AJ , Parker MM , Moffet HH , Gilliam LK , Dlott R . Continuous glucose monitor use prevents glycemic deterioration in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther, 2022; 24: 332–37.

Evans M , Welsh Z , Seibold A . Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diabetes Ther, 2022; 13: 1175–85.

Martens T , Beck RW , Bailey R , et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA, 2021; 325: 2262–72.

Pasquel FJ , Lansang MC , Dhatariya K , Umpierrez GE . Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol, 2021; 9: 174–88.

Lombardi A , Agarwal S , Schechter C , Tomer Y. In-Hospital Hyperglycemia is associated with worse outcomes in patients admitted with COVID-19. Diabetes Care 2022 Aug 30;dc220708. doi: 10.2337/dc22-0708. Online ahead of print.

Bode B , Garrett V , Messler J , et al. Glycemic Characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol, 2020; 14: 813–21.

Villard O , Breton MD , Rao S , et al. Accuracy of a factory-calibrated continuous glucose monitor in individuals with diabetes on hemodialysis. Diabetes Care, 2022; 45: 1666-69.

Boughton CK , Daly A , Thabit H , et al. Day-to-day variability of insulin requirements in the inpatient setting: observations during fully closed-loop insulin delivery. Diabetes Obes Metab, 2021; 23: 1978–82.

Bally L , Thabit H , Hartnell S , et al. Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med, 2018; 379: 547–56.

Boughton CK , Bally L , Martignoni F , et al. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol, 2019; 7: 368–77.

Phillip M , Nimri R , Bergenstal RM , et al. Consensus recommendations for the use of automated insulin delivery (AID) technologies in clinical practice. Endocr Rev 2022 Sep 6;bnac022. doi: 10.1210/endrev/bnac022. Online ahead of print.